We're so glad you're here! This site is to help anyone diagnosed with Medullary Thyroid Cancer and their caregivers find valuable information and support. If you'd like to connect with others with MTC, please consider joining our very active Facebook Group. You don't have to go through this alone!
If you don't yet have a copy, please download the American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma, aka "The Guidelines." This is the MTC Bible. Read it and know it and it will help you and your doctor ensure you get the proper treatment.
Lastly, please consider looking into being seen by an MTC expert. We do our best to keep a running list of what we call "Centers of Excellence." These are doctors and facilities that are properly trained and experienced enough to treat MTC patients. It's one of the most important decisions you can make on your journey.
"... (pralsetinib) as first-line treatment in patients with RET fusion-positive NSCLC; Final analysis from the Phase 1/2 ARROW clinical trial of pralsetinib ..."
"Retevmo (selpercatinib, formerly known as LOXO-292) (pronounced reh-TEHV-moh) is a highly selective and potent RET kinase inhibitor with central ..."
"Which one of the following data sets are you most eager to learn more about at ASCO? Phase I study of LOXO-292 - a highly selective RET Inhibitor ..."
"Oral presentation at ASCO Annual Meeting to feature final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO (pralsetinib) as ..."
"Phase 3 LIBRETTO-432 study evaluating Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive NSCLC to be featured in the Plenary ..."
This website is intended for educational purposes only. It is not intended, nor should it be interpreted, as medical advice or instructions of any kind. Readers are advised to consult their own medical doctor(s) for all matters involving their health and medical care.